Washington: In what could be a blow to President Donald Trump, The firm won’t seek an emergency use authorisation for its vaccine before November 25, its CEO told the Financial Times on Wednesday, NDTV reported.
CEO Stephane Bancel told the newspaper: “November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA (Food and Drug Administration) – assuming that the safety data is good, i.e. a vaccine is deemed to be safe.”
Trump was very keen that the vaccine be ready before the November 3 vote. Now that nothing like this seems to be on the horizon, experts are concerned that his administration may attempt to interfere with the regulatory process for political reasons.
Moderna’s vaccine is one of the 11 experimental ones in the final stage trials.
